Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Zilebesiran (ALN-AGT01) in Hypertension
NCT03934307Phase 1Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- May 2019
- Primary completion
- Apr 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zilebesiran in hypertension (HTN) (7 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Number of Participants with Adverse Events at 18 months. Started May 2019; status: completed.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03934307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934307.